Company intelligence / Profile preview

3CKD Bio

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

3CKD Bio is a pre-clinical stage biotechnology company dedicated to developing transformative therapies for patients suffering from chronic kidney disease (CKD). The company focuses on identifying and modulating novel biological pathways involved in renal fibrosis and disease progression. By leveraging proprietary insights into kidney pathophysiology, 3CKD Bio aims to create small molecule interventions that can halt or reverse the decline of kidney function. Their current research efforts are directed toward high-unmet-need areas such as diabetic nephropathy and polycystic kidney disease.

Therapeutic areas: Nephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 3CKD Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3CKD Bio.

Explore the full profile